Immunosuppressive therapy with Certican (everolimus) after lung transplantation.

Trial Profile

Immunosuppressive therapy with Certican (everolimus) after lung transplantation.

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Apr 2016

At a glance

  • Drugs Everolimus (Primary)
  • Indications Lung transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Apr 2016 Results published in the American Journal of Transplantation
    • 07 Dec 2011 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.
    • 07 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top